EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis
Recurrence and metastasis remain the major cause of cancer mortality. Even for early-stage lung cancer, adjuvant chemotherapy yields merely slight increase to patient survival. EF-hand domain-containing protein D2 (EFHD2) has recently been implicated in recurrence of patients with stage I lung adeno...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-07-01
|
| Series: | Redox Biology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231720303785 |
| _version_ | 1818434491875590144 |
|---|---|
| author | Chi-Chen Fan Sheng-Ta Tsai Chen-Yuan Lin Ling-Chu Chang Juan-Cheng Yang Guan‐Yu Chen Yuh-Pyng Sher Shao-Chun Wang Michael Hsiao Wei‐Chao Chang |
| author_facet | Chi-Chen Fan Sheng-Ta Tsai Chen-Yuan Lin Ling-Chu Chang Juan-Cheng Yang Guan‐Yu Chen Yuh-Pyng Sher Shao-Chun Wang Michael Hsiao Wei‐Chao Chang |
| author_sort | Chi-Chen Fan |
| collection | DOAJ |
| description | Recurrence and metastasis remain the major cause of cancer mortality. Even for early-stage lung cancer, adjuvant chemotherapy yields merely slight increase to patient survival. EF-hand domain-containing protein D2 (EFHD2) has recently been implicated in recurrence of patients with stage I lung adenocarcinoma. In this study, we investigated the correlation between EFHD2 and chemoresistance in non-small cell lung cancer (NSCLC). High expression of EFHD2 was significantly associated with poor overall survival of NSCLC patients with chemotherapy in in silica analysis. Ectopic EFHD2 overexpression increased cisplatin resistance, whereas EFHD2 knockdown improved chemoresponse. Mechanistically, EFHD2 induced the production of NADPH oxidase 4 (NOX4) and in turn the increase of intracellular reactive oxygen species (ROS), consequently activating membrane expression of the ATP-binding cassette subfamily C member 1 (ABCC1) for drug efflux. Non-steroidal anti-inflammatory drug (NSAID) ibuprofen suppressed EFHD2 expression by leading to the proteasomal and lysosomal degradation of EFHD2 through a cyclooxygenase (COX)-independent mechanism. Combining ibuprofen with cisplatin enhanced antitumor responsiveness in a murine xenograft model in comparison with the individual treatment. In conclusion, we demonstrate that EFHD2 promotes chemoresistance through the NOX4-ROS-ABCC1 axis and therefore developing EFHD2-targeting strategies may offer a new avenue to improve adjuvant chemotherapy of lung cancer. |
| first_indexed | 2024-12-14T16:37:50Z |
| format | Article |
| id | doaj.art-6417aba6fe7e4f2d9cc2fcb446d63216 |
| institution | Directory Open Access Journal |
| issn | 2213-2317 |
| language | English |
| last_indexed | 2024-12-14T16:37:50Z |
| publishDate | 2020-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Redox Biology |
| spelling | doaj.art-6417aba6fe7e4f2d9cc2fcb446d632162022-12-21T22:54:24ZengElsevierRedox Biology2213-23172020-07-0134101571EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axisChi-Chen Fan0Sheng-Ta Tsai1Chen-Yuan Lin2Ling-Chu Chang3Juan-Cheng Yang4Guan‐Yu Chen5Yuh-Pyng Sher6Shao-Chun Wang7Michael Hsiao8Wei‐Chao Chang9Department of Superintendent Office, Mackay Memorial Hospital, Taipei, Taiwan; Department of Medical Laboratory Science and Biotechnology, Yuanpei University, Hsinchu, TaiwanGenomics Research Center, Academia Sinica, Taipei, TaiwanDepartment of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan; School of Pharmacy, China Medical University, Taichung, TaiwanCenter for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan; Department of Biological Science and Technology, China Medical University, Taichung, TaiwanDepartment of Superintendent Office, Mackay Memorial Hospital, Taipei, Taiwan; Department of Medical Laboratory Science and Biotechnology, Yuanpei University, Hsinchu, Taiwan; Department of Post-Baccalaureate Chinese Medicine, China Medical University, Taichung, Taiwan; Chinese Medicine Research and Development Center, China Medical University Hospital, Taichung, TaiwanChinese Medicine Research and Development Center, China Medical University Hospital, Taichung, TaiwanCenter for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Chinese Medicine Research Center, China Medical University, Taichung, Taiwan; Research Center for Chinese Herbal Medicine, China Medical University, Taichung, TaiwanCenter for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA; Department of Biotechnology, Asia University, Taichung, TaiwanGenomics Research Center, Academia Sinica, Taipei, Taiwan; Department of Biochemistry, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Corresponding author. Genomics Research Center, Academia Sinica, No. 128, Academia Road, Section 2, Nankang, Taipei, Taiwan.Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan; Corresponding author. Center for Molecular Medicine, China Medical University Hospital, No. 2, Yude Road, North District, Taichung, Taiwan.Recurrence and metastasis remain the major cause of cancer mortality. Even for early-stage lung cancer, adjuvant chemotherapy yields merely slight increase to patient survival. EF-hand domain-containing protein D2 (EFHD2) has recently been implicated in recurrence of patients with stage I lung adenocarcinoma. In this study, we investigated the correlation between EFHD2 and chemoresistance in non-small cell lung cancer (NSCLC). High expression of EFHD2 was significantly associated with poor overall survival of NSCLC patients with chemotherapy in in silica analysis. Ectopic EFHD2 overexpression increased cisplatin resistance, whereas EFHD2 knockdown improved chemoresponse. Mechanistically, EFHD2 induced the production of NADPH oxidase 4 (NOX4) and in turn the increase of intracellular reactive oxygen species (ROS), consequently activating membrane expression of the ATP-binding cassette subfamily C member 1 (ABCC1) for drug efflux. Non-steroidal anti-inflammatory drug (NSAID) ibuprofen suppressed EFHD2 expression by leading to the proteasomal and lysosomal degradation of EFHD2 through a cyclooxygenase (COX)-independent mechanism. Combining ibuprofen with cisplatin enhanced antitumor responsiveness in a murine xenograft model in comparison with the individual treatment. In conclusion, we demonstrate that EFHD2 promotes chemoresistance through the NOX4-ROS-ABCC1 axis and therefore developing EFHD2-targeting strategies may offer a new avenue to improve adjuvant chemotherapy of lung cancer.http://www.sciencedirect.com/science/article/pii/S2213231720303785EFHD2RecurrenceAdjuvant chemotherapyNOX4ABCC1Ibuprofen |
| spellingShingle | Chi-Chen Fan Sheng-Ta Tsai Chen-Yuan Lin Ling-Chu Chang Juan-Cheng Yang Guan‐Yu Chen Yuh-Pyng Sher Shao-Chun Wang Michael Hsiao Wei‐Chao Chang EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis Redox Biology EFHD2 Recurrence Adjuvant chemotherapy NOX4 ABCC1 Ibuprofen |
| title | EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis |
| title_full | EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis |
| title_fullStr | EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis |
| title_full_unstemmed | EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis |
| title_short | EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis |
| title_sort | efhd2 contributes to non small cell lung cancer cisplatin resistance by the activation of nox4 ros abcc1 axis |
| topic | EFHD2 Recurrence Adjuvant chemotherapy NOX4 ABCC1 Ibuprofen |
| url | http://www.sciencedirect.com/science/article/pii/S2213231720303785 |
| work_keys_str_mv | AT chichenfan efhd2contributestononsmallcelllungcancercisplatinresistancebytheactivationofnox4rosabcc1axis AT shengtatsai efhd2contributestononsmallcelllungcancercisplatinresistancebytheactivationofnox4rosabcc1axis AT chenyuanlin efhd2contributestononsmallcelllungcancercisplatinresistancebytheactivationofnox4rosabcc1axis AT lingchuchang efhd2contributestononsmallcelllungcancercisplatinresistancebytheactivationofnox4rosabcc1axis AT juanchengyang efhd2contributestononsmallcelllungcancercisplatinresistancebytheactivationofnox4rosabcc1axis AT guanyuchen efhd2contributestononsmallcelllungcancercisplatinresistancebytheactivationofnox4rosabcc1axis AT yuhpyngsher efhd2contributestononsmallcelllungcancercisplatinresistancebytheactivationofnox4rosabcc1axis AT shaochunwang efhd2contributestononsmallcelllungcancercisplatinresistancebytheactivationofnox4rosabcc1axis AT michaelhsiao efhd2contributestononsmallcelllungcancercisplatinresistancebytheactivationofnox4rosabcc1axis AT weichaochang efhd2contributestononsmallcelllungcancercisplatinresistancebytheactivationofnox4rosabcc1axis |